In the second installment of an interview with Jacinda Abdul-Mutakabbir, PharmD, MPH, she continues the discussion around limited to no health care engagement due to these factors, and the importance of translating data from the bench to bedside when looking at disease and infection prevention.
Jacinda Abdul-Mutakabbir, PharmD, MPH, provides insights on her recently published study on this topic and how the 2 are connected.
Jose Alexander, MD, offers insights on these antimicrobial combinations when treating against this bacterium.
Emily Olsen, PhD, offers some insights on this underdiagnosed infection, including describing antimicrobial studies, particularly in biofilm and intracellular environments. Her findings look to create a standardized approach for treating all forms of the different presentations of bartonellosis.
Athena Hobbs, PharmD, BCIDP, looked at this issue through the lens of treating urinary tract infections.
In part 2 of the conversation, David Relman, MD, discusses the importance of the research and medical communities in shaping future work in this area as well as the potential severe consequences of Mirror Life in a worse case scenario.
David Relman, MD, discusses the theoretical issues of "mirror life," how the scientific community could potentially research natural chirality synthetic life, and how mirror molecules may be a way to extract beneficial research from the concept.
César de la Fuente, PhD, provides insights on the promising work of his lab as they accelerate the speed of finding new antimicrobial molecules.
At ASM Microbe 2025, Pelumi Oladipo discusses E marmotae’s reduced motility, misidentification as E coli, and the diagnostic tools closing the gap.
Presented at ASM Microbe, Pelumi Oladipo's study identifies the first North American human case of E marmotae infection and introduces methods to improve species-level diagnosis.
Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP) talks about how his team developed a test to identify fungi, and how they utilize it to diagnose, make treatment adjustments, and rule out hospital acquired infections.
Margie Lee, DVM, MS, PhD, wants young researchers and providers to know that despite the current environment, this is not the first time science has had to deal with a challenges to research and funding.
TAXIS Pharmaceuticals Chief Scientific Officer Ajit Parhi, PhD, discusses dihydrofolate reductase inhibitors as a novel approach to combat resistant Neisseria gonorrhoeae.
Rodney Rohde, PhD, SM(ASCP), SVCM, MBCM, FACSc, discusses the ongoing concerns about the federal government’s hold on funding for research and the potential chilling effect that it may have on laboratory professionals and deciding on careers, especially in areas such as public health. He also talks about locating and engaging in potential alternative resources for research funding.
At ASM Microbe 2025, Meghan Starolis, PhD, discusses her presentation on antiviral testing including the advantages and limitations to genotypic and phenotypic testing and looking at how this can affect the immunocompromised population.
American Society for Microbiology (ASM) CEO Stefano Bertuzzi, PhD, MPH, talks about ASM's comprehensive scientific program, the networking opportunities at the meeting, and the unique format ASM plans to roll out for the 2026 conference.
In a wide-ranging interview, Susan Weiss, PhD, talks about winning the ASM Lifetime Achievement award, her work on coronaviruses, and her concerns around federal government funding and how it may shake up and limit basic science research.
At ASM Microbe 2025, a Puerto Rico study linked increased fungal spore concentrations to rises in viral respiratory infections, suggesting potential early warning utility.
At ASM Microbe 2025, a cross-sectional study highlighted Burkholderia cepacia dominance, widespread antibiotic resistance, and key risk factors, including invasive device use and patient demographics.
At the ASM Microbe conference, Mike Bromley, PhD, offers some insights on the importance of a One Health approach addressing the growing antifungal resistance to azoles and Aspergillus fumigatus because of the connection between crop spraying and the rise of resistance.
At ASM Microbe 2025, researchers underscored the role of NAAT in outpatient CDI diagnosis and raised concerns over PPI-related risk in older, health care–associated cases.
A study presented at ASM Microbe 2025 questions the clinical value of adding enzyme immunoassays to PCR-based CDI diagnostics amid sensitivity concerns.
Presented at ASM Microbe 2025, a bioinformatics study highlights 9 human miRNAs capable of binding and potentially inhibiting both hepatitis C and bovine viral diarrhea viruses.
New ASM data show indoor environments are associated with quick and frequent pathogen contamination of the common respiratory device.
An interview with a study author on unique associations between county infrastructures and COVID-19 fatality rates.
The device may help clinicians differentiate between past infections and co-infections during the upcoming flu season.
New findings on an available 15-minute test show an approximate 81% sensitivity in detection of SARS-CoV-2.
New findings from the ASM 2021 World Microbe Forum suggest the emergency-authorized platform can capably detected the highly transmissible UK-borne variant.
Investigators looked at data from 3 analyses showed a reduction in mortality was observed across a spectrum of baseline oxygen requirements, at different timeframes, over the course of the pandemic, and in various geographies.
As little as 10 minutes of ocean swimming can replace the skin microbiome, and bacteria can persist on skin for 24 hours after swimming.
